Indeed, approximately 60–80% of patients whose tumor samples contain somatic mutations in the kinase domain of epidermal growth factor receptor (EGFR) gene are responsive to EGFR tyrosine kinase inhibitors (TKI) gefitinib and erlotinib [6]. The gene discussed is EGFR; the disease is neoplasm.